{"nctId":"NCT01830140","briefTitle":"A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2013-07"},"conditions":["Glaucoma","Ocular Hypertension"],"count":466,"armGroups":[{"label":"Bimatoprost 0.01%","type":"EXPERIMENTAL","interventionNames":["Drug: Bimatoprost 0.01%"]},{"label":"Bimatoprost 0.03%","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bimatoprost 0.03%"]}],"interventions":[{"name":"Bimatoprost 0.01%","otherNames":["LUMIGAN® 0.01%"]},{"name":"Bimatoprost 0.03%","otherNames":["LUMIGAN® 0.03%"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of glaucoma or ocular hypertension\n\nExclusion Criteria:\n\n* Active ocular disease other than glaucoma or ocular hypertension\n* Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye","description":"Macroscopic conjunctival hyperemia (eye redness) is graded in each eye on a 5-point scale (Scale 0 to +3: none, trace, mild, moderate, severe). An increase (worsening) in macroscopic conjunctival hyperemia is defined as an increase in macroscopic conjunctival hyperemia grade of at least 1 from baseline in either eye.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":null},{"groupId":"OG001","value":"39.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":233},"commonTop":["Conjunctival Hyperaemia","Eye Pruritus"]}}}